• Home
  • Search Results
  • Oxyphylla A Promotes Degradation of α-Synuclein for Neuroprotection via Activation of Immunoproteasome.

Oxyphylla A Promotes Degradation of α-Synuclein for Neuroprotection via Activation of Immunoproteasome.

Aging and disease (2020-06-04)
Hefeng Zhou, Shengnan Li, Chuwen Li, Xuanjun Yang, Haitao Li, Hanbing Zhong, Jia-Hong Lu, Simon Ming-Yuen Lee

Parkinson's disease (PD), the second most common neurodegenerative disorder, is neuropathologically characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the presence of Lewy bodies in surviving neurons. α-synuclein (α-syn) is the major component of Lewy bodies and its deposition in neurons is critical pathological event in the pathogenesis of PD. Herein, we reported that Oxyphylla A, a novel lead compound from the fruit of Alpinia oxyphylla, significantly promoted α-syn degradation in a cellular PD model. When exploring the molecular pathways, we found that Oxyphylla A promoted α-syn degradation in a ubiquitin proteasome system (UPS)-dependent and autophagy-independent manner. We further confirmed that Oxyphylla A enhanced UPS activity by upregulating 20S subunit PSMB8 expression. A mechanism study revealed that Oxyphylla A activated the PKA/Akt/mTOR pathway to trigger PSMB8 expression and enhance UPS activity. Finally, we illustrated that Oxyphylla A alleviated the accumulation of both Triton-soluble and Triton-insoluble forms of α-syn and protected against α-syn-induced neurotoxicity in A53T α-syn transgenic mice. These findings suggest that the activation of UPS, via small molecular UPS enhancers including Oxyphylla A, may be a therapeutic strategy for intervention against PD and related diseases.

Product Number
Product Description

Brij® L23, main component: tricosaethylene glycol dodecyl ether
Cytotoxicity Detection Kit (LDH), suitable for protein quantification, suitable for cell analysis, detection, sufficient for ≤2,000 tests
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Thiazolyl Blue Tetrazolium Bromide, 98%
Doxycycline hyclate
Anti-Tyrosine Hydroxylase Antibody, clone LNC1, ascites fluid, clone LNC1, Chemicon®
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)
Chloroquine diphosphate salt, powder or crystals, 98.5-101.0% (EP)